<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Motion sickness</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Motion sickness</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Motion sickness</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrian J Priesol, MD, FRCPC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel G Deschler, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Motion sickness is a syndrome that occurs in response to real or perceived motion, which can include gastrointestinal, central nervous system, and autonomic symptoms.</p><p>Motion sickness is considered a physiologic form of dizziness, since it is not indicative of a disease process and can be induced in nearly all normal human subjects. There is enormous variability in susceptibility to motion sickness, as it may be produced with minimal provocation in some individuals but can be very difficult to elicit in others.</p><p>The symptoms of motion sickness were first described by Hippocrates. They frequently occur during boat travel, and the principal symptom (nausea) is derived from the Greek word for ship (naus).</p><p>This topic discusses the pathogenesis, epidemiology, clinical presentation, diagnosis, prevention, and treatment of motion sickness. A possibly related disorder, disembarkment syndrome (sometimes called mal de debarquement syndrome), and other causes of vertigo and dizziness are discussed separately. (See  <a class="medical medical_review" href="/d/html/5101.html" rel="external">"Causes of vertigo"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The brain receives numerous inputs that are used to estimate the motion and spatial orientation of the head. The principal sensory signals that contribute to this process are vestibular cues from the labyrinth, visual information, and somatosensory cues. Afferent information derived from the labyrinth encodes both angular motion (sensed by the semicircular canals) and linear acceleration and gravitational force (sensed by the otolith organs).</p><p>During active movements such as locomotion, the motor command generated by the brain (sometimes referred to as a corollary discharge or efference copy) is also used to estimate the motion of the head and body. During self-generated movements in normal subjects, the motor command and sensory feedback are congruent, and the brain can generate a stable and accurate estimate of head motion and orientation.</p><p>In the absence of active movements, the brain's estimate of motion is primarily based upon vestibular, visual, and somatosensory information. When these three sensory cues are not congruent, a sensory conflict is generated in the brain, and it is hypothesized that this conflict underlies the symptoms of motion sickness [<a href="#rid1">1-3</a>].</p><p>As an example, if the visual system indicates that a person is stationary (eg, viewing the interior of a cabin on a ship), but the vestibular system senses ongoing head movements (eg, due to motion of the ship), the vestibular and visual cues conflict and engender symptoms of motion sickness. Furthermore, if the semicircular canals and otolith organs produce sensory cues that are incongruous, motion sickness can be evoked that is independent of vision.</p><p>Similarly, if the visual system indicates movement (eg, moving a microscope slide, engaging in virtual reality games or rides, watching a point-of-view movie) but the vestibular system does not, a visually induced motion sickness can result.</p><p>Labyrinthine inputs are clearly crucial to the development of motion sickness, since experimental animals with inactivated semicircular canals or otolith organs do not develop the syndrome [<a href="#rid4">4,5</a>], nor did a group of deaf subjects who were presumed to lack peripheral vestibular function [<a href="#rid6">6</a>]. Conversely, blind subjects have a predilection to motion sickness similar to those with normal vision, suggesting that the contribution of visual information to this syndrome is less critical [<a href="#rid7">7</a>]. Movements that are most likely to elicit motion sickness include low-frequency rotations and translations and novel motion patterns, particularly those involving head rotations about two axes simultaneously (resulting in cross-coupled, or Coriolis, forces) [<a href="#rid8">8</a>].</p><p>The anatomic basis for motion sickness is not well understood. It is presumed to depend upon connections between the central vestibular system in the brainstem and cerebellum and the autonomic and emetic centers in the brain [<a href="#rid9">9</a>]. Projections from the nodulus and uvula of the cerebellum to the brainstem that modulate a central vestibular process referred to as "velocity storage" may be critical for the development of motion sickness [<a href="#rid10">10,11</a>]. Histamine, acetylcholine, and norepinephrine appear to be the critical neurotransmitters involved in the production of motion sickness [<a href="#rid12">12</a>]. Gamma-aminobutyric acid (GABA) also plays a role in motion sickness through effects on the velocity storage integrator [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Motion sickness can be induced in almost all people with sufficient provocation. Individuals vary in their susceptibility to motion sickness, and certain characteristics are correlated with this susceptibility.</p><p class="headingAnchor" id="H2608616750"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>The incidence of motion sickness depends upon the specific conditions encountered. The following observations illustrate the findings in different settings:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 20,029 passengers on 114 voyages at sea (six ships, two hovercraft, and one jet foil), 21 percent felt "slightly unwell," 4 percent felt "quite ill," 4 percent felt "absolutely dreadful," and 7 percent experienced vomiting [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 3256 passengers on 56 bus trips, 28 percent reported feeling ill, 13 percent reported nausea, and 2 percent reported vomiting [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 923 passengers on 38 commercial airline flights, 16 percent reported feeling ill, 8 percent reported nausea, and 0.5 percent reported vomiting [<a href="#rid16">16</a>].</p><p></p><p class="headingAnchor" id="H2147628330"><span class="h2">Risk factors</span></p><p class="headingAnchor" id="H4"><span class="h3">Patient factors</span></p><p class="bulletIndent1"><span class="glyph">●</span>Sex – Females are generally more susceptible to motion sickness than males [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age – Children less than two years old are typically resistant to motion sickness; the incidence peaks at approximately nine years of age and then decreases throughout adulthood [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic factors – Genetic variants have been associated with increased susceptibility to motion sickness; a genome-wide study of 80,494 individuals found 35 single-nucleotide polymorphisms (SNPs) that were associated with motion sickness [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Migraine – Migraine sufferers are more susceptible to motion sickness [<a href="#rid20">20-23</a>]. In one study, 50 percent of migraine sufferers reported a history of motion sickness versus 20 percent of persons with tension headache [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hormonal factors – Individuals are particularly susceptible to motion sickness during pregnancy; susceptibility may also be affected by the menstrual cycle and by use of oral contraceptives [<a href="#rid25">25,26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Expectations – The risk of motion sickness may be affected by an individual’s expectations of whether or not they will become ill. As an example, a controlled trial found that naval cadets who were told they were unlikely to experience seasickness were at decreased risk of developing motion sickness [<a href="#rid27">27</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h3">Environmental factors</span></p><p class="bulletIndent1"><span class="glyph">●</span>Type of motion – As discussed above, low-frequency motion and certain directions of motion are more likely to induce motion sickness. In a study of air travelers, the magnitude of low-frequency lateral and vertical motion was associated with motion sickness [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Body position – Lying supine, at least on a ship, may decrease susceptibility to motion sickness [<a href="#rid28">28</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The syndrome of motion sickness is easily recognized, since it includes stereotypic symptoms in the setting of passive motion or in the setting of visual perception of motion without actual movement.</p><p>The most characteristic symptom of motion sickness is nausea. This can begin subtly; it is often described as a sense of being aware of one’s stomach. Other common features include a feeling of warmth and malaise [<a href="#rid16">16</a>]. Nausea can progress to vomiting, which is occasionally severe. Some patients may experience headache with their motion sickness.</p><p>Other symptoms may include nonvertiginous dizziness, belching, increased salivation, diaphoresis, and a general feeling of malaise [<a href="#rid25">25,29</a>]. Hyperventilation is a common associated feature and can induce dyspnea, paresthesias, and feelings of impending doom.</p><p>Physical signs usually cannot be detected, although pallor may be present. Subtle autonomic changes can be quantified with appropriate testing and include increased perspiration, slowing of gastric emptying, and postural hypotension [<a href="#rid30">30,31</a>].</p><p>Symptoms typically subside after 36 to 72 hours of continuous exposure, but they can recur upon returning to the pre-exposure environment (eg, returning to land after a sea voyage) [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H2117403592"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of motion sickness is clinical, based upon the presence of typical symptoms (eg, nausea, sweating, malaise) in response to externally imposed motion or other stimulus. If a patient has a previous history of motion sickness and a typical presentation, then no further evaluation is needed.</p><p>However, if a patient with no prior motion sickness suddenly becomes prone to motion sickness, then evaluation for migraine, which is associated with increased susceptibility to motion sickness, is warranted. There is evidence that better control of migraine can reduce motion sickness susceptibility [<a href="#rid32">32,33</a>].</p><p class="headingAnchor" id="H3514008408"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>True vertigo is a distinguishing characteristic of other disorders, such as vestibular migraine and vestibulopathy, that may be confused with motion sickness. However, true vertigo is not a feature of motion sickness.</p><p>Vestibular migraine shares some clinical features with motion sickness, but patients with vestibular migraine usually have a migraine-type headache and true vertigo rather than nonvertiginous dizziness. (See  <a class="medical medical_review" href="/d/html/3356.html" rel="external">"Vestibular migraine", section on 'Clinical features'</a>.)</p><p>Vestibulopathy can increase visual-vestibular conflict and should be considered in patients who report motion sickness but who have not been prone to it in the past. Vestibulopathy may be a benign, self-limited disorder (vestibular neuritis) or may result from exposure to ototoxic medications. If vestibulopathy is suspected, referral to a neurologist or vestibular specialist is indicated. Patients with vestibulopathies typically experience symptoms with all types of motion, not solely with externally imposed or perceived motion, as in motion sickness.<em> </em>(See  <a class="medical medical_review" href="/d/html/5101.html" rel="external">"Causes of vertigo", section on 'Peripheral etiologies'</a>.)</p><p class="headingAnchor" id="H3579686971"><span class="h1">APPROACH TO MANAGEMENT</span><span class="headingEndMark"> — </span>A patient may consult a clinician about prevention of motion sickness or about treatment of acute motion sickness. Treatment of acute motion sickness is often ineffective, and therefore an emphasis should be placed on prevention [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H1347595160"><span class="h2">Prevention</span><span class="headingEndMark"> — </span>Patients vary considerably in their susceptibility to motion sickness:</p><p class="bulletIndent1"><span class="glyph">●</span>Significant motion sickness – Some patients report a prior history of motion sickness symptoms that are distressing and interfere with their ability to function. (See <a class="local">'Patients with a history of significant motion sickness'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No significant motion sickness – Other patients do not report a prior history of motion sickness or have had mild symptoms that do not interfere with their ability to function. (See <a class="local">'Patients without a history of significant motion sickness'</a> below.)</p><p></p><p>The management of the patient should take into account whether or not they have a history of significant motion sickness. All patients should be counseled about environmental modification and all patients should be offered complementary and alternative treatments. However, because all medications used to prevent motion sickness are sedating, we base the decision about using medication upon the likelihood that the patient will be affected by motion sickness. In patients without a past history of significant motion sickness, the risk of illness is low and does not justify the risk of side effects from medication.</p><p class="headingAnchor" id="H2564738536"><span class="h3">Patients with a history of significant motion sickness</span><span class="headingEndMark"> — </span>Patients who have experienced significant motion sickness in the past often ask clinicians for advice on how to prevent motion sickness. In general, interventions that are useful in preventing motion sickness can be divided into environmental modifications, complementary and alternative treatments, and medications.</p><p class="headingAnchor" id="H1267355637"><span class="h4">Environmental modification</span><span class="headingEndMark"> — </span>Patients should be advised about environmental modification measures, which include:</p><p class="bulletIndent1"><span class="glyph">●</span>Looking at the horizon or a distant, stationary object.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of reading or looking at a screen while in a moving environment, as this can increase conflict between vestibular and visual cues.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Selecting seats where motion is the least. In a boat, lower deck and midship cabins are recommended. In a car, the front seat is recommended. In a plane, a seat over the front edge of the wing is recommended. If travelling by train or bus, forward facing seats are recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Driving the car is better than being the passenger, presumably because visual information is consistent with vestibular motion detection. When a passenger, it is preferable to be in the front seat with one’s eyes on the road, as if driving the car.</p><p></p><p>Data on the efficacy of environmental modifications are limited, but studies have suggested benefit from looking at a stable visual reference point, avoidance of reading while in motion, and driving rather than being a passenger [<a href="#rid35">35-38</a>]. In addition, seating locations with more motion are associated with higher risk for motion sickness [<a href="#rid15">15,16</a>].</p><p class="headingAnchor" id="H3343880942"><span class="h4">Complementary and alternative treatments</span><span class="headingEndMark"> — </span>In addition to environmental modification, we discuss the use of ginger and acupressure bands with patients prone to motion sickness, as these measures are well tolerated and may be beneficial.</p><p>Specifically, we advise patients suck on hard ginger candies if they experience or anticipate experiencing symptoms of motion sickness. Acupressure bands are typically applied to both wrists prophylactically but can also be worn after symptoms have begun.</p><p>Randomized trials both in experimental motion sickness and in naval cadets at sea have found benefit with pretreatment with 1 to 2 grams of ginger [<a href="#rid39">39,40</a>]. The mechanism of benefit with ginger is uncertain. Some studies suggest that it has an effect on gastric motility [<a href="#rid41">41,42</a>], while other studies suggest a central effect of its active constituents on serotonin receptor subtypes [<a href="#rid43">43</a>].</p><p>Acupressure for motion sickness applies pressure at the P6 acupressure point on the anterior wrist (three fingerbreadths proximal to the proximal wrist fold, between the palmaris longus and flexor carpi radialis tendons)  (<a class="graphic graphic_picture graphicRef82211" href="/d/graphic/82211.html" rel="external">picture 1</a>) either by manual pressure or with a wrist band. It has been reported to be effective for motion sickness in some [<a href="#rid44">44-46</a>], but not all [<a href="#rid47">47-49</a>], controlled trials. A randomized trial with a device that applies electrical stimulation to the P6 point found no benefit [<a href="#rid50">50</a>].</p><p>While these results raise the possibility that acupressure may be of benefit for motion sickness, trials of this sort are difficult to perform with adequate blinding and allocation concealment. It remains uncertain whether acupressure provides a benefit beyond a placebo effect [<a href="#rid30">30,31</a>].</p><p class="headingAnchor" id="H107930409"><span class="h4">Scopolamine or antihistamines</span><span class="headingEndMark"> — </span>Medications are helpful in the prevention of motion sickness but are often sedating, so the patient’s likelihood of experiencing motion sickness must be balanced against the possibility of side effects. The best studied and most commonly used options are <a class="drug drug_general" data-topicid="9915" href="/d/drug information/9915.html" rel="external">scopolamine</a> and antihistamines.</p><p>The specific medication chosen will depend upon the circumstances (eg, the duration of the exposure and the acceptability of drowsiness or other side effects). As an example, the extended duration of action of the <a class="drug drug_general" data-topicid="9915" href="/d/drug information/9915.html" rel="external">scopolamine</a> patch may be beneficial if the exposure to motion will be prolonged, such as with an ocean voyage. Although shorter-acting and potentially more sedating, antihistamines have the advantages of lower cost, over-the-counter availability, and relatively rapid onset of action. Antihistamines are therefore frequently used when a limited exposure to motion is anticipated.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9915" href="/d/drug information/9915.html" rel="external">Scopolamine</a> (transdermal) – Scopolamine is usually prescribed as a 1 mg transdermal patch, applied behind the ear at least four hours (preferably 12 hours) before exposure to motion. Patches should be replaced every 72 hours if needed. Because motion sickness may cause gastric hypomotility, the transdermal route is advantageous. For patients with symptoms that persist despite a single patch, a second patch may be added; this increased dose is generally well tolerated [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1">Transdermal <a class="drug drug_general" data-topicid="9915" href="/d/drug information/9915.html" rel="external">scopolamine</a> is generally well tolerated. Potential side effects of scopolamine include sedation, blurred vision, dry mouth and, in older adults, confusion and urinary retention. Some patients develop dermatitis from the scopolamine patch. Scopolamine is contraindicated in people at risk for angle-closure glaucoma.</p><p></p><p class="bulletIndent1">A meta-analysis of 14 trials involving 1025 subjects found that <a class="drug drug_general" data-topicid="9915" href="/d/drug information/9915.html" rel="external">scopolamine</a> was more effective in preventing motion sickness than placebo (risk ratio [RR] 0.48, 95% CI 0.32 to 0.73) but not more effective than antihistamines [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antihistamines – A number of antihistamines can be given to prevent motion sickness. We use <a class="drug drug_general" data-topicid="8896" href="/d/drug information/8896.html" rel="external">dimenhydrinate</a> or <a class="drug drug_general" data-topicid="9597" href="/d/drug information/9597.html" rel="external">meclizine</a>, 25 mg orally every six to eight hours as needed, with the first dose taken 30 to 60 minutes prior to anticipated travel. If sedation is excessive, the dose may be reduced to 12.5 mg or even 6.25 mg. Other antihistamines used for motion sickness include <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a>, <a class="drug drug_general" data-topicid="8860" href="/d/drug information/8860.html" rel="external">chlorpheniramine</a> [<a href="#rid53">53</a>], cyclizine [<a href="#rid54">54</a>], and cinnarizine [<a href="#rid55">55</a>]. Dimenhydrinate is available as a chewable tablet. Cinnarizine is not available in the United States but is widely used in other countries; cyclizine is not available in the United States or Canada.</p><p></p><p class="bulletIndent1">Nonsedating antihistamines (eg, <a class="drug drug_general" data-topicid="9236" href="/d/drug information/9236.html" rel="external">cetirizine</a>, <a class="drug drug_general" data-topicid="9572" href="/d/drug information/9572.html" rel="external">loratadine</a>, <a class="drug drug_general" data-topicid="8445" href="/d/drug information/8445.html" rel="external">fexofenadine</a>) do <strong>not</strong> appear to be effective for the treatment of motion sickness [<a href="#rid56">56,57</a>].</p><p></p><p class="bulletIndent1">Side effects are mainly related to anticholinergic effects and include sedation, blurred vision, dry mouth and, in older adults, confusion and urinary retention. One small study suggested that cyclizine may be less sedating than <a class="drug drug_general" data-topicid="8896" href="/d/drug information/8896.html" rel="external">dimenhydrinate</a> at a dose that is equally effective for symptoms of motion sickness [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1">Antihistamines are effective for the prevention of motion sickness but may cause more sedation than <a class="drug drug_general" data-topicid="9915" href="/d/drug information/9915.html" rel="external">scopolamine</a> [<a href="#rid59">59</a>].</p><p></p><p class="headingAnchor" id="H3278279777"><span class="h5">Patients who have failed transdermal scopolamine and antihistamines</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9820" href="/d/drug information/9820.html" rel="external">Promethazine</a> is less well studied for prevention of motion sickness but is a reasonable choice if transdermal <a class="drug drug_general" data-topicid="9915" href="/d/drug information/9915.html" rel="external">scopolamine</a> and antihistamines are not effective. It may be more sedating than antihistamines. In addition to sedation, side effects of promethazine include anticholinergic and extrapyramidal effects. (See  <a class="medical medical_review" href="/d/html/2538.html" rel="external">"Characteristics of antiemetic drugs", section on 'Antihistamines'</a>.)</p><p>Oral <a class="drug drug_general" data-topicid="9915" href="/d/drug information/9915.html" rel="external">scopolamine</a> is used infrequently but is an option if the duration of exposure to motion will be brief and antihistamines are not tolerated or are ineffective. Typical dosing is 0.25 to 0.8 mg one hour before exposure to motion and then 0.25 to 0.8 mg three times daily as needed and tolerated. Oral scopolamine has been discontinued in the United States but may be available from compounding pharmacies.</p><p>Other medications that have been shown to be effective for prevention in small trials include <a class="drug drug_general" data-topicid="9345" href="/d/drug information/9345.html" rel="external">diazepam</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, and <a class="drug drug_general" data-topicid="10243" href="/d/drug information/10243.html" rel="external">rizatriptan</a> (in people who have migraines); <a class="drug drug_general" data-topicid="9719" href="/d/drug information/9719.html" rel="external">ondansetron</a> is <strong>not</strong> effective in the prevention of motion sickness [<a href="#rid33">33,60-63</a>].</p><p class="headingAnchor" id="H2584564988"><span class="h5">Patients who need to avoid sedation</span><span class="headingEndMark"> — </span>Preventing motion sickness can be a particular problem in patients who need to perform tasks such as flying a plane or acting as crew on a ship, since the medications used are all potentially sedating [<a href="#rid64">64-66</a>]. <a class="drug drug_general" data-topicid="8896" href="/d/drug information/8896.html" rel="external">Dimenhydrinate</a>, for example, may have particularly negative effects on performance [<a href="#rid67">67</a>].</p><p>In such individuals, we would use a sedating antihistamine in combination with a stimulant such as <a class="drug drug_general" data-topicid="9833" href="/d/drug information/9833.html" rel="external">pseudoephedrine</a> or <a class="drug drug_general" data-topicid="9114" href="/d/drug information/9114.html" rel="external">ephedrine</a>. This combination is available in some over-the-counter preparations (eg, <a class="drug drug_general" data-topicid="8860" href="/d/drug information/8860.html" rel="external">chlorpheniramine</a> and pseudoephedrine). Although <a class="drug drug_general" data-topicid="99959" href="/d/drug information/99959.html" rel="external">amphetamine</a> has been studied in this population, we do not use amphetamines to prevent the side effects of drugs used for motion sickness.</p><p>Limited data suggest that stimulants may counteract the side effects of sedating medicines used to prevent motion sickness. As an example, one trial found that administering <a class="drug drug_general" data-topicid="99959" href="/d/drug information/99959.html" rel="external">amphetamine</a>, but not <a class="drug drug_general" data-topicid="9833" href="/d/drug information/9833.html" rel="external">pseudoephedrine</a>, with <a class="drug drug_general" data-topicid="9820" href="/d/drug information/9820.html" rel="external">promethazine</a> appeared to prevent the sleepiness and impairment of psychomotor performance seen with promethazine alone [<a href="#rid68">68</a>]. Another trial reported that <a class="drug drug_general" data-topicid="9114" href="/d/drug information/9114.html" rel="external">ephedrine</a> decreased sleepiness and improved performance in patients administered <a class="drug drug_general" data-topicid="8860" href="/d/drug information/8860.html" rel="external">chlorpheniramine</a>, although it did not add to the effectiveness of chlorpheniramine in treating motion sickness [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H642166003"><span class="h3">Patients without a history of significant motion sickness</span><span class="headingEndMark"> — </span>Although infrequently, some patients may ask about preventing motion sickness, even if motion sickness has not been a significant problem previously.</p><p>In such cases, it is reasonable to provide information about environmental modification measures and complementary and alternative treatments, which are discussed above. (See <a class="local">'Environmental modification'</a> above and <a class="local">'Complementary and alternative treatments'</a> above.)</p><p>We generally do <strong>not</strong> recommend medications to patients who are not prone to significant motion sickness because of the potential for sedation and other anticholinergic side effects.</p><p class="headingAnchor" id="H1361772368"><span class="h3">Pregnant patients</span><span class="headingEndMark"> — </span>As mentioned above, pregnant patients may be particularly susceptible to motion sickness. Medications that are felt to be safe for the treatment of morning sickness can also be used for motion sickness. These include the antihistamines <a class="drug drug_general" data-topicid="9597" href="/d/drug information/9597.html" rel="external">meclizine</a> and <a class="drug drug_general" data-topicid="8896" href="/d/drug information/8896.html" rel="external">dimenhydrinate</a>. Alternatives include <a class="drug drug_general" data-topicid="9915" href="/d/drug information/9915.html" rel="external">scopolamine</a> and <a class="drug drug_general" data-topicid="9820" href="/d/drug information/9820.html" rel="external">promethazine</a>. However, scopolamine should be avoided in patients with severe preeclampsia due to increased risk of eclamptic seizures [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/d/html/6792.html" rel="external">"Nausea and vomiting of pregnancy: Clinical findings and evaluation"</a>.)</p><p class="headingAnchor" id="H947669428"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>In a patient with symptomatic motion sickness, the same interventions employed for prevention of significant symptoms are used: environmental modification, complementary and alternative treatments, and rapidly acting medications such as antihistamines. (See <a class="local">'Patients with a history of significant motion sickness'</a> above.)</p><p>Medications used to prevent motion sickness may be less effective in patients with acute symptoms because motion sickness induces gastric stasis, which interferes with the absorption of drugs given orally.</p><p><a class="drug drug_general" data-topicid="9820" href="/d/drug information/9820.html" rel="external">Promethazine</a> can be used if antihistamines are ineffective, although the data are limited [<a href="#rid71">71</a>]. Promethazine has the advantage of availability as an intramuscular injection or as a suppository. However, there is a risk of soft tissue injury or gangrene with intramuscular administration. Dosing in all forms is 25 mg, given every 8 to 12 hours as needed. </p><p class="headingAnchor" id="H18610937"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16731.html" rel="external">"Patient education: Motion sickness (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and pathogenesis</strong> – Motion sickness is a syndrome that occurs in response to real or perceived motion, which can include gastrointestinal, central nervous system, and autonomic symptoms. In the absence of active, self-generated movements, the brain's estimate of motion is primarily based upon vestibular, visual, and somatosensory information. When these three sensory cues are not congruent, a sensory conflict is generated in the brain, and it is hypothesized that this conflict underlies the symptoms of motion sickness. (See <a class="local">'Introduction'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Motion sickness can be induced in almost all people with sufficient provocation. Individuals vary in their susceptibility to motion sickness. In general, females (especially during pregnancy), children older than two years, and migraine sufferers are more susceptible. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation and diagnosis</strong> – Common symptoms of motion sickness include nausea, headache, warmth, and malaise. Other symptoms may include a nonvertiginous sense of dizziness, belching, increased salivation, and diaphoresis. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1">The diagnosis of motion sickness is clinical, based upon the presence of typical symptoms in response to externally imposed motion or perceived motion. If a patient has a previous history of motion sickness and a typical presentation, then no further evaluation is needed. However, if a patient with no prior motion sickness suddenly becomes prone to motion sickness, then evaluation for migraine, which is associated with increased susceptibility to motion sickness, is warranted. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management: Emphasis on prevention</strong> – Treatment of acute motion sickness is often ineffective, and therefore an emphasis should be placed on prevention. Our approach to the prevention of motion sickness depends upon the patient’s past susceptibility to motion sickness (see <a class="local">'Prevention'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>History of significant motion sickness</strong> – Some patients report a prior history of motion sickness symptoms that are distressing and interfere with their ability to function. In such patients, we employ:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Environmental modifications (eg, looking at the horizon, avoidance of reading, and selecting a seat where motion is the least). (See <a class="local">'Environmental modification'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Complementary and alternative treatments (ginger candies and acupressure bands). (See <a class="local">'Complementary and alternative treatments'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Medications – The best studied and most commonly used medication options are <a class="drug drug_general" data-topicid="9915" href="/d/drug information/9915.html" rel="external">scopolamine</a> and antihistamines. The specific medication chosen will depend upon the circumstances (eg, the duration of the exposure and the acceptability of drowsiness or other side effects). (See <a class="local">'Scopolamine or antihistamines'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>No history of significant motion sickness</strong> – Other patients do not report a prior history of motion sickness or have had mild symptoms that do not interfere with their ability to function. For such patients, we provide information about environmental modification measures and complementary and alternative treatments. We generally do <strong>not</strong> recommend medications to patients who are not prone to significant motion sickness because of the potential for sedation and other anticholinergic side effects. (See <a class="local">'Patients without a history of significant motion sickness'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy</strong> – Pregnant individuals may be particularly susceptible to motion sickness. Medications that are felt to be safe for the treatment of morning sickness can also be used for motion sickness. These include the antihistamines <a class="drug drug_general" data-topicid="9597" href="/d/drug information/9597.html" rel="external">meclizine</a> and <a class="drug drug_general" data-topicid="8896" href="/d/drug information/8896.html" rel="external">dimenhydrinate</a>. (See <a class="local">'Pregnant patients'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Oman CM. Motion sickness: a synthesis and evaluation of the sensory conflict theory. Can J Physiol Pharmacol 1990; 68:294.</a></li><li><a class="nounderline abstract_t">Flanagan MB, May JG, Dobie TG. The role of vection, eye movements and postural instability in the etiology of motion sickness. J Vestib Res 2004; 14:335.</a></li><li><a class="nounderline abstract_t">Shupak A, Gordon CR. Motion sickness: advances in pathogenesis, prediction, prevention, and treatment. Aviat Space Environ Med 2006; 77:1213.</a></li><li><a class="nounderline abstract_t">Miller EF 2nd, Graybiel A. Semicircular canals as a primary etiological factor in motion sickness. Aerosp Med 1972; 43:1065.</a></li><li><a class="nounderline abstract_t">Brizzee KR, Igarashi M. Effect of macular ablation on frequency and latency of motion-induced emesis in the squirrel monkey. Aviat Space Environ Med 1986; 57:1066.</a></li><li><a class="nounderline abstract_t">James W. The sense of dizziness in deaf-mutes. Am J Otol 1882; 4:239.</a></li><li><a class="nounderline abstract_t">Graybiel A. Susceptibility to acute motion sickness in blind persons. Aerosp Med 1970; 41:650.</a></li><li><a class="nounderline abstract_t">Woodman PD, Griffin MJ. Effect of direction of head movement on motion sickness caused by Coriolis stimulation. Aviat Space Environ Med 1997; 68:93.</a></li><li><a class="nounderline abstract_t">Balaban CD, Porter JD. Neuroanatomic substrates for vestibulo-autonomic interactions. J Vestib Res 1998; 8:7.</a></li><li><a class="nounderline abstract_t">Dai M, Kunin M, Raphan T, Cohen B. The relation of motion sickness to the spatial-temporal properties of velocity storage. Exp Brain Res 2003; 151:173.</a></li><li><a class="nounderline abstract_t">Cohen B, Dai M, Raphan T. The critical role of velocity storage in production of motion sickness. Ann N Y Acad Sci 2003; 1004:359.</a></li><li><a class="nounderline abstract_t">Takeda N, Morita M, Hasegawa S, et al. Neuropharmacology of motion sickness and emesis. A review. Acta Otolaryngol Suppl 1993; 501:10.</a></li><li><a class="nounderline abstract_t">Cohen B, Dai M, Yakushin SB, Raphan T. Baclofen, motion sickness susceptibility and the neural basis for velocity storage. Prog Brain Res 2008; 171:543.</a></li><li><a class="nounderline abstract_t">Lawther A, Griffin MJ. A survey of the occurrence of motion sickness amongst passengers at sea. Aviat Space Environ Med 1988; 59:399.</a></li><li><a class="nounderline abstract_t">Turner M, Griffin MJ. Motion sickness in public road transport: passenger behavior and susceptibility. Ergonomics 1999; 42:444.</a></li><li><a class="nounderline abstract_t">Turner M, Griffin MJ, Holland I. Airsickness and aircraft motion during short-haul flights. Aviat Space Environ Med 2000; 71:1181.</a></li><li><a class="nounderline abstract_t">Cooper C, Dunbar N, Mira M. Sex and seasickness on the Coral Sea. Lancet 1997; 350:892.</a></li><li><a class="nounderline abstract_t">Golding JF. Motion sickness. Handb Clin Neurol 2016; 137:371.</a></li><li><a class="nounderline abstract_t">Hromatka BS, Tung JY, Kiefer AK, et al. Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis. Hum Mol Genet 2015; 24:2700.</a></li><li><a class="nounderline abstract_t">Barabas G, Matthews WS, Ferrari M. Childhood migraine and motion sickness. Pediatrics 1983; 72:188.</a></li><li><a class="nounderline abstract_t">Drummond PD. Triggers of motion sickness in migraine sufferers. Headache 2005; 45:653.</a></li><li><a class="nounderline abstract_t">Marcus DA, Furman JM, Balaban CD. Motion sickness in migraine sufferers. Expert Opin Pharmacother 2005; 6:2691.</a></li><li><a class="nounderline abstract_t">Drummond PD, Granston A. Facial pain increases nausea and headache during motion sickness in migraine sufferers. Brain 2004; 127:526.</a></li><li><a class="nounderline abstract_t">Kayan A, Hood JD. Neuro-otological manifestations of migraine. Brain 1984; 107 ( Pt 4):1123.</a></li><li><a class="nounderline abstract_t">Gahlinger PM. Motion sickness. How to help your patients avoid travel travail. Postgrad Med 1999; 106:177.</a></li><li><a class="nounderline abstract_t">Grunfeld E, Gresty MA. Relationship between motion sickness, migraine and menstruation in crew members of a "round the world" yacht race. Brain Res Bull 1998; 47:433.</a></li><li><a class="nounderline abstract_t">Eden D, Zuk Y. Seasickness as a self-fulfilling prophecy: raising self-efficacy to boost performance at sea. J Appl Psychol 1995; 80:628.</a></li><li><a class="nounderline abstract_t">Gahlinger PM. Cabin location and the likelihood of motion sickness in cruise ship passengers. J Travel Med 2000; 7:120.</a></li><li><a class="nounderline abstract_t">Money KE. Motion sickness. Physiol Rev 1970; 50:1.</a></li><li><a class="nounderline abstract_t">Spinks AB, Wasiak J, Villanueva EV, Bernath V. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev 2007; :CD002851.</a></li><li><a class="nounderline abstract_t">Ungs TJ. Simulator induced syndrome in Coast Guard aviators. Aviat Space Environ Med 1988; 59:267.</a></li><li><a class="nounderline abstract_t">Lee SH, Jeong SH, Kim JS, et al. Effect of Prophylactic Medication on Associated Dizziness and Motion Sickness in Migraine. Otol Neurotol 2018; 39:e45.</a></li><li><a class="nounderline abstract_t">Furman JM, Marcus DA, Balaban CD. Rizatriptan reduces vestibular-induced motion sickness in migraineurs. J Headache Pain 2011; 12:81.</a></li><li><a class="nounderline abstract_t">Murdin L, Golding J, Bronstein A. Managing motion sickness. BMJ 2011; 343:d7430.</a></li><li><a class="nounderline abstract_t">Turner M, Griffin MJ. Motion sickness in public road transport: the relative importance of motion, vision and individual differences. Br J Psychol 1999; 90 ( Pt 4):519.</a></li><li><a class="nounderline abstract_t">Bos JE, MacKinnon SN, Patterson A. Motion sickness symptoms in a ship motion simulator: effects of inside, outside, and no view. Aviat Space Environ Med 2005; 76:1111.</a></li><li><a class="nounderline abstract_t">Perrin P, Lion A, Bosser G, et al. Motion sickness in rally car co-drivers. Aviat Space Environ Med 2013; 84:473.</a></li><li><a class="nounderline abstract_t">Golding JF, Bles W, Bos JE, et al. Motion sickness and tilts of the inertial force environment: active suspension systems vs. active passengers. Aviat Space Environ Med 2003; 74:220.</a></li><li><a class="nounderline abstract_t">Grøntved A, Brask T, Kambskard J, Hentzer E. Ginger root against seasickness. A controlled trial on the open sea. Acta Otolaryngol 1988; 105:45.</a></li><li><a class="nounderline abstract_t">Lien HC, Sun WM, Chen YH, et al. Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular vection. Am J Physiol Gastrointest Liver Physiol 2003; 284:G481.</a></li><li><a class="nounderline abstract_t">Holtmann S, Clarke AH, Scherer H, Höhn M. The anti-motion sickness mechanism of ginger. A comparative study with placebo and dimenhydrinate. Acta Otolaryngol 1989; 108:168.</a></li><li><a class="nounderline abstract_t">Ghayur MN, Gilani AH. Pharmacological basis for the medicinal use of ginger in gastrointestinal disorders. Dig Dis Sci 2005; 50:1889.</a></li><li><a class="nounderline abstract_t">Abdel-Aziz H, Windeck T, Ploch M, Verspohl EJ. Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum. Eur J Pharmacol 2006; 530:136.</a></li><li><a class="nounderline abstract_t">Hu S, Stritzel R, Chandler A, Stern RM. P6 acupressure reduces symptoms of vection-induced motion sickness. Aviat Space Environ Med 1995; 66:631.</a></li><li><a class="nounderline abstract_t">Stern RM, Jokerst MD, Muth ER, Hollis C. Acupressure relieves the symptoms of motion sickness and reduces abnormal gastric activity. Altern Ther Health Med 2001; 7:91.</a></li><li><a class="nounderline abstract_t">Bertalanffy P, Hoerauf K, Fleischhackl R, et al. Korean hand acupressure for motion sickness in prehospital trauma care: a prospective, randomized, double-blinded trial in a geriatric population. Anesth Analg 2004; 98:220.</a></li><li><a class="nounderline abstract_t">Bruce DG, Golding JF, Hockenhull N, Pethybridge RJ. Acupressure and motion sickness. Aviat Space Environ Med 1990; 61:361.</a></li><li><a class="nounderline abstract_t">Warwick-Evans LA, Masters IJ, Redstone SB. A double-blind placebo controlled evaluation of acupressure in the treatment of motion sickness. Aviat Space Environ Med 1991; 62:776.</a></li><li><a class="nounderline abstract_t">Miller KE, Muth ER. Efficacy of acupressure and acustimulation bands for the prevention of motion sickness. Aviat Space Environ Med 2004; 75:227.</a></li><li><a class="nounderline abstract_t">Estrada A, LeDuc PA, Curry IP, et al. Airsickness prevention in helicopter passengers. Aviat Space Environ Med 2007; 78:408.</a></li><li><a class="nounderline abstract_t">Bar R, Gil A, Tal D. Safety of double-dose transdermal scopolamine. Pharmacotherapy 2009; 29:1082.</a></li><li><a class="nounderline abstract_t">Spinks A, Wasiak J. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev 2011; 2011:CD002851.</a></li><li><a class="nounderline abstract_t">Buckey JC, Alvarenga D, Cole B, Rigas JR. Chlorpheniramine for motion sickness. J Vestib Res 2004; 14:53.</a></li><li><a class="nounderline abstract_t">Brand JJ, Colquhoun WP, Gould AH, Perry WL. (--)-Hyoscine and cyclizine as motion sickness remedies. Br J Pharmacol Chemother 1967; 30:463.</a></li><li><a class="nounderline abstract_t">Lucertini M, Mirante N, Casagrande M, et al. The effect of cinnarizine and cocculus indicus on simulator sickness. Physiol Behav 2007; 91:180.</a></li><li><a class="nounderline abstract_t">Kohl RL, Homick JL, Cintron N, Calkins DS. Lack of effects of astemizole on vestibular ocular reflex, motion sickness, and cognitive performance in man. Aviat Space Environ Med 1987; 58:1171.</a></li><li><a class="nounderline abstract_t">Cheung BS, Heskin R, Hofer KD. Failure of cetirizine and fexofenadine to prevent motion sickness. Ann Pharmacother 2003; 37:173.</a></li><li><a class="nounderline abstract_t">Weinstein SE, Stern RM. Comparison of marezine and dramamine in preventing symptoms of motion sickness. Aviat Space Environ Med 1997; 68:890.</a></li><li><a class="nounderline abstract_t">Brainard A, Gresham C. Prevention and treatment of motion sickness. Am Fam Physician 2014; 90:41.</a></li><li><a class="nounderline abstract_t">McClure JA, Lycett P, Baskerville JC. Diazepam as an anti-motion sickness drug. J Otolaryngol 1982; 11:253.</a></li><li><a class="nounderline abstract_t">Albert EG. Phenytoin for the prevention of motion sickness. Med J Aust 2003; 178:575.</a></li><li><a class="nounderline abstract_t">Muth ER, Elkins AN. High dose ondansetron for reducing motion sickness in highly susceptible subjects. Aviat Space Environ Med 2007; 78:686.</a></li><li><a class="nounderline abstract_t">Hershkovitz D, Asna N, Shupak A, et al. Ondansetron for the prevention of seasickness in susceptible sailors: an evaluation at sea. Aviat Space Environ Med 2009; 80:643.</a></li><li><a class="nounderline abstract_t">Nicholson AN, Stone BM, Turner C, Mills SL. Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med 2002; 73:570.</a></li><li><a class="nounderline abstract_t">Cowings PS, Toscano WB, DeRoshia C, Miller NE. Promethazine as a motion sickness treatment: impact on human performance and mood states. Aviat Space Environ Med 2000; 71:1013.</a></li><li><a class="nounderline abstract_t">Paule MG, Chelonis JJ, Blake DJ, Dornhoffer JL. Effects of drug countermeasures for space motion sickness on working memory in humans. Neurotoxicol Teratol 2004; 26:825.</a></li><li><a class="nounderline abstract_t">Gordon CR, Gonen A, Nachum Z, et al. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance. J Psychopharmacol 2001; 15:167.</a></li><li><a class="nounderline abstract_t">Paul MA, MacLellan M, Gray G. Motion-sickness medications for aircrew: impact on psychomotor performance. Aviat Space Environ Med 2005; 76:560.</a></li><li><a class="nounderline abstract_t">Buckey JC Jr, Alvarenga DL, MacKenzie TA. Chlorpheniramine and ephedrine in combination for motion sickness. J Vestib Res 2007; 17:301.</a></li><li class="breakAll">Scopolamine - scopolamine patch. US Food and Drug Administration (FDA) approved product information. Revised March, 2019. US National Library of Medicine. Available at: https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=163accb7-45e6-4d97-844d-72b606677008&amp;type=pdf (Accessed on September 28, 2021).</li><li><a class="nounderline abstract_t">Davis JR, Jennings RT, Beck BG, Bagian JP. Treatment efficacy of intramuscular promethazine for space motion sickness. Aviat Space Environ Med 1993; 64:230.</a></li></ol></div><div id="topicVersionRevision">Topic 6853 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2178753" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Motion sickness: a synthesis and evaluation of the sensory conflict theory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15328447" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The role of vection, eye movements and postural instability in the etiology of motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17183916" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Motion sickness: advances in pathogenesis, prediction, prevention, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5076605" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Semicircular canals as a primary etiological factor in motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2878654" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of macular ablation on frequency and latency of motion-induced emesis in the squirrel monkey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The sense of dizziness in deaf-mutes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5446920" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Susceptibility to acute motion sickness in blind persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9125096" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Effect of direction of head movement on motion sickness caused by Coriolis stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9416584" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Neuroanatomic substrates for vestibulo-autonomic interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12783152" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The relation of motion sickness to the spatial-temporal properties of velocity storage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14662476" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The critical role of velocity storage in production of motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8447218" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Neuropharmacology of motion sickness and emesis. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18718351" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Baclofen, motion sickness susceptibility and the neural basis for velocity storage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3390095" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A survey of the occurrence of motion sickness amongst passengers at sea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10048305" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Motion sickness in public road transport: passenger behavior and susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11439716" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Airsickness and aircraft motion during short-haul flights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9310639" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Sex and seasickness on the Coral Sea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27638085" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25628336" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Genetic variants associated with motion sickness point to roles for inner ear development, neurological processes and glucose homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6866603" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Childhood migraine and motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15953297" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Triggers of motion sickness in migraine sufferers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16316307" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Motion sickness in migraine sufferers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14749288" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Facial pain increases nausea and headache during motion sickness in migraine sufferers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6334543" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neuro-otological manifestations of migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10533517" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Motion sickness. How to help your patients avoid travel travail.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10052571" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Relationship between motion sickness, migraine and menstruation in crew members of a "round the world" yacht race.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7592232" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Seasickness as a self-fulfilling prophecy: raising self-efficacy to boost performance at sea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11179940" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cabin location and the likelihood of motion sickness in cruise ship passengers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4904269" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17636710" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Scopolamine (hyoscine) for preventing and treating motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3355483" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Simulator induced syndrome in Coast Guard aviators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29227453" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of Prophylactic Medication on Associated Dizziness and Motion Sickness in Migraine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20862509" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rizatriptan reduces vestibular-induced motion sickness in migraineurs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22138695" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Managing motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10629944" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Motion sickness in public road transport: the relative importance of motion, vision and individual differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16370260" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Motion sickness symptoms in a ship motion simulator: effects of inside, outside, and no view.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23713212" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Motion sickness in rally car co-drivers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12650268" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Motion sickness and tilts of the inertial force environment: active suspension systems vs. active passengers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3277342" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Ginger root against seasickness. A controlled trial on the open sea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12576305" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular vection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2683568" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The anti-motion sickness mechanism of ginger. A comparative study with placebo and dimenhydrinate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16187193" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pharmacological basis for the medicinal use of ginger in gastrointestinal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16364290" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7575310" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : P6 acupressure reduces symptoms of vection-induced motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11452572" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Acupressure relieves the symptoms of motion sickness and reduces abnormal gastric activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14693623" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Korean hand acupressure for motion sickness in prehospital trauma care: a prospective, randomized, double-blinded trial in a geriatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2339974" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acupressure and motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1930060" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A double-blind placebo controlled evaluation of acupressure in the treatment of motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15018290" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficacy of acupressure and acustimulation bands for the prevention of motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17484344" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Airsickness prevention in helicopter passengers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19698013" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Safety of double-dose transdermal scopolamine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21678338" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Scopolamine (hyoscine) for preventing and treating motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15156097" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Chlorpheniramine for motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4860708" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : (--)-Hyoscine and cyclizine as motion sickness remedies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17434541" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The effect of cinnarizine and cocculus indicus on simulator sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3122717" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Lack of effects of astemizole on vestibular ocular reflex, motion sickness, and cognitive performance in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12549941" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Failure of cetirizine and fexofenadine to prevent motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9327113" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparison of marezine and dramamine in preventing symptoms of motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25077501" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prevention and treatment of motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7131636" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Diazepam as an anti-motion sickness drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12765507" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Phenytoin for the prevention of motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17679566" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : High dose ondansetron for reducing motion sickness in highly susceptible subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19601507" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Ondansetron for the prevention of seasickness in susceptible sailors: an evaluation at sea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12056673" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Central effects of cinnarizine: restricted use in aircrew.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11051308" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Promethazine as a motion sickness treatment: impact on human performance and mood states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15451046" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Effects of drug countermeasures for space motion sickness on working memory in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11565623" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15945400" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Motion-sickness medications for aircrew: impact on psychomotor performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18626140" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Chlorpheniramine and ephedrine in combination for motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18626140" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Chlorpheniramine and ephedrine in combination for motion sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8447805" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment efficacy of intramuscular promethazine for space motion sickness.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
